• Image
  • Image
  • Image

Partnerships

Galderma is a leading pharmaceutical company focused exclusively on dermatology. For over 30 years, the company has harnessed insights of scientific discovery to develop innovative dermatology solutions for patients and healthcare professionals.

Our dedicated staff, valued partnerships, scientific leadership and good luck have brought us great success. To further that success, dermatology company Galderma is engaged in active outreach to the best scientific organisations worldwide.

Because we embrace the best ideas in science, building effective collaborations of all kinds – from early stage development to late stage licensing – is a priority for Galderma. The company forms licensing partnerships around innovative product candidates and technologies. Galderma is most interested in opportunities that have a well-validated target, a novel mechanism of action, well-characterised pharmaceutical properties, a strong intellectual property position and preclinical or clinical data. Dermatology company Galderma’s technology licensing agreements must be science driven, provide access to technology that extends our existing programs and are consistent with our research strategies. 

Working together with Galderma

Backed by Galderma’s financial strength and stability, and that of our shareholders, Nestlé, your product will have the necessary support to realise its true potential. We are well-positioned to secure and dedicate resources to the right opportunities.

Yet financial stability alone is not enough. The success of your opportunity also depends on a strong infrastructure which dermatology company Galderma can provide. Our research expertise is backed by development capabilities in many countries around the world. Galderma moves quickly to evaluate the potential of a compound in human studies and conducts definitive clinical trials with clearly-defined endpoints for those compounds that advance. We offer the benefit of years of experience with the U.S. Food and Drug Administration and other regulatory authorities around the world. Our state-of-the-art production facilities and our experienced manufacturing staff can expedite your product’s launch. Dermatology company Galderma is also able to provide the commercialisation experience necessary for a successful launch. .

Galderma was founded in 1981 with the goal of establishing a pharmaceutical company exclusively focused on the field of dermatology. Today as a fully owned company under Nestlé Skin Health, Galderma has approximately 5,000 employees in 33 affiliates around the world with five manufacturing sites and the largest R&D facility dedicated exclusively to dermatology. Galderma’s important investments in research and development, extensive product portfolio, global presence and expertise in three key segments (prescription drugs, over-the-counter drugs and aesthetic and corrective solutions) have positioned the company as a leader in dermatology.

Prescription Products

Prescription dermatology solutions represent the core of Galderma’s business. Galderma is seeking innovative new compounds to develop first-in-class or best-in-class products that provide therapeutic solutions to a wide variety of dermatological conditions.
Disease target areas include:

  • Acne

  • Psoriasis, scalp psoriasis and steroid-responsive dermatoses

  • Rosacea

  • Onychomycosis (fungal nail infections)

  • Pigmentary disorders

  • Skin cancer

  • Medical solutions for skin senescence (or ageing skin).

Our criteria for prescription dermatology development programs include:

  • Topical or systemic

  • Small molecule or biological

  • Safety profiled

  • Known mechanism of action

  • Comparative in vitro and in vivo pharmacology data versus reference products

  • Proof of concept in humans

We are also seeking to acquire or in-license programs or technologies to support and complement our internal research efforts, such as:

  • Compound libraries

  • Compound library management (purity, concentration, storage, composition, biased libraries)

  • Pathology-oriented cellular assays and in vivo models

  • Validated targets (e.g. GCPR’s, ION channels, enzymes, nuclear receptors)

Aesthetic & Corrective Solutions

To provide innovative medical dermatology solutions that meet the needs of patients and healthcare professional, dermatology company Galderma evolved its traditional pharmaceutical business model several years ago to incorporate the aesthetic & corrective market. In 2001, the company entered into the emerging field of photo-dynamic therapy, an initiative that progressively accelerated with increased activity and investment. In 2008, Galderma began promoting and selling a botulinum toxin product in Latin America. This activity grew further with the approval and launch of the product in Europe in 2009. Through active partnerships, the dermatology company also expanded its offering to include a range of hyaluronic acid-based dermal fillers and a topical anesthetic product. In 2011, Galderma acquired Q-Med AB, a Swedish medical device company and leader in the aesthetic market.

Beyond skin senescence, Galderma is also focused on developing medical solutions for corrective and aesthetic applications in most of the other therapeutic areas that the company serves, including acne, rosacea, psoriasis and steroid-responsive dermatoses, pigmentary disorders, onychomycosis and skin cancer,  that help healthcare providers optimise patient outcomes.



For more information on partnerships with Galderma globally, or to contact Galderma's international office to introduce a proposal, please visit the international Galderma website

Discover more about Galderma (UK) Ltd, part of an international dermatology company providing dermatology solutions and aesthetic and corrective products internationally. 

 

Corporate responsibility

Growing a responsible dermatological community

Discover some of the positive initiatives we are involved in across the world

Read

Video

We are committed

See all videos